0001493152-24-002173.txt : 20240112 0001493152-24-002173.hdr.sgml : 20240112 20240112145503 ACCESSION NUMBER: 0001493152-24-002173 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240112 FILED AS OF DATE: 20240112 DATE AS OF CHANGE: 20240112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pershing Edward CENTRAL INDEX KEY: 0001689739 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36457 FILM NUMBER: 24531781 MAIL ADDRESS: STREET 1: 2220 SOUTHERLAND AVE CITY: KNOXVILLE STATE: TN ZIP: 37919 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PROVECTUS BIOPHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000315545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 900031917 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 800 S. GAY STREET STREET 2: SUITE 1610 CITY: KNOXVILLE STATE: TN ZIP: 37929 BUSINESS PHONE: (866) 594-5999 MAIL ADDRESS: STREET 1: 800 S. GAY STREET STREET 2: SUITE 1610 CITY: KNOXVILLE STATE: TN ZIP: 37929 FORMER COMPANY: FORMER CONFORMED NAME: PROVECTUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020417 FORMER COMPANY: FORMER CONFORMED NAME: ZAMAGE DIGITAL IMAGING INC DATE OF NAME CHANGE: 20011126 FORMER COMPANY: FORMER CONFORMED NAME: SPM GROUP INC DATE OF NAME CHANGE: 19920703 4 1 ownership.xml X0508 4 2024-01-12 0 0000315545 PROVECTUS BIOPHARMACEUTICALS, INC. PVCT 0001689739 Pershing Edward 800 S. GAY STREET, SUITE 1610 KNOXVILLE TN 37929 1 0 0 0 0 8% Unsecured Convertible Promissory Note 2.862 2024-01-12 4 M 0 125000 0 D 2023-01-12 2024-01-12 Series D-1 Convertible Preferred Stock 47180 1575000 D Series D-1 Convertible Preferred Stock 2024-01-12 4 M 0 47180 0 A 2024-01-12 Common Stock 471800 914468 D Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note due 2023 (the "2022 Note") at any time while the 2022 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2022 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2022 Note. The 2022 Note was issued pursuant to the Issuer's 2022 Financing. On January 12, 2024, the 2022 Note was converted into 47,180 shares of Series D-1 Preferred Stock. /s/ Edward Pershing 2024-01-12